The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of a pooled synthetic long peptide mutant KRAS vaccine combined with balstilimab/botensilimab in metastatic pancreatic cancer and metastatic MMR-proficient colorectal cancer in the maintenance setting.
 
Kai-li Liang
No Relationships to Disclose
 
Amanda Huff
No Relationships to Disclose
 
Maureen Berg
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
Julie Nauroth
No Relationships to Disclose
 
Kyle Friedman
No Relationships to Disclose
 
Amy Thomas
No Relationships to Disclose
 
Madeline Figlewski
No Relationships to Disclose
 
Dan Laheru
No Relationships to Disclose
 
Elizabeth Jaffee
Stock and Other Ownership Interests - ABMETA Therapeutics; Adventris
Consulting or Advisory Role - Achilles Therapeutics; Dragonfly Therapeutics; Medically Home; Mestag Therapeutics; NeoTX; NEUVOGEN; SURGE Therapeutics
Research Funding - Breast Cancer Research Foundation; Bristol-Myers Squibb; Lucence Diagnostics; Roche
Patents, Royalties, Other Intellectual Property - I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.
Other Relationship - Break Through Cancer; CPRIT; Parker Institute; Parker Institute
 
Neeha Zaidi
Stock and Other Ownership Interests - Adventris
Consulting or Advisory Role - Genentech; HalioDx; Ipsen
 
Nilofer Azad
Stock and Other Ownership Interests - Cage Pharma; Irazu; Tempus
Consulting or Advisory Role - Agenus; Astellas Pharma; AstraZeneca; BeiGene; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Taiho Pharmaceutical; Tempus
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Revolution Medicines (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics